Role of Suppressor of Cytokine Signaling-1 In Murine Atherosclerosis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Grothusen, Christina ^a   Schuett, Harald ^a   Hillmer, Anja ^a   Lumpe, Stefan ^a   Grote, Karsten ^a   Ballmaier, Matthias ^a   Bleich, Andre ^a   Glage, Silke ^a   Tietge, Uwe J F ^b   Luchtefeld, Maren ^a   Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MATURATION; CHOLESTEROL DIET; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, LY; ATHEROSCLEROSIS; CYTOKINES; DIET, HIGH-FAT; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MACROPHAGE ACTIVATION; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; NEUTROPHILS; RECEPTORS, LDL; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MURINAE; MUS;

EID: 84871644701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051608     Document Type: Article

References (32)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Yoshimura A, Naka T, Kubo M, (2007) SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465.
3. Whyte CS, Bishop ET, Ruckerl D, Gaspar-Pereira S, Barker RN, et al. (2011) Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol 90: 845-854.
4. Sachithanandan N, Graham KL, Galic S, Honeyman JE, Fynch SL, et al. (2011) Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes 60: 2023-2031.
5. Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, et al. (2009) Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 525-531.
6. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, et al. (2009) Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206: 2067-2077.
7. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, et al (2004) Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110: 3493-3500.
8. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, et al. (2010) Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation 122: 1621-1628.
9. Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, et al. (2012) Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation 126: 952-962.
10. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, et al. (2011) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32: 281-290.
11. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, et al. (2000) Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem 275: 10077-10084.
12. Havel RJ, Eder HA, Bragdon JH, (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.
13. Esterbauer H, Striegl G, Puhl H, Rotheneder M, (1989) Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6: 67-75.
14. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, et al. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545.
15. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, (2007) Schieffer B, et al (2007) Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 101: 1104-1112.
16. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, et al. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117: 195-205.
17. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, et al. (1999) SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98: 609-616.
18. Geissmann F, Jung S, Littman DR, (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
19. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, et al. (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A 95: 14395-14399.
20. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, et al. (1995) A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15: 1512-1531.
21. Ross R, Harker L, (1976) Hyperlipidemia and atherosclerosis. Science 193: 1094-1100.
22. Swirski FK, Weissleder R, Pittet MJ, (2009) Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1424-1432.
23. Chinen T, Komai K, Muto G, Morita R, Inoue N, et al. (2011) Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat Commun 2: 190.
24. Gonzalez-Leon MC, Soares-Schanoski A, del Fresno C, Cimadevila A, Gomez-Pina V, et al. (2006) Nitric oxide induces SOCS-1 expression in human monocytes in a TNF-alpha-dependent manner. J Endotoxin Res 12: 296-306.
25. Drevets DA, Schawang JE, Mandava VK, Dillon MJ, Leenen PJ, (2010) Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features. J Immunol 185: 2432-2441.
26. Zhang Y, Ma CJ, Ni L, Zhang CL, Wu XY, et al. (2011) Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol 186: 3093-3103.
27. Daugherty A, Pure E, Delfel-Butteiger D, Chen S, Leferovich J, et al. (1997) The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J Clin Invest 100: 1575-1580.
28. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, et al. (2001) Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21: 1011-1016.
29. Metcalf D, Alexander WS, Elefanty AG, Nicola NA, Hilton DJ, et al. (1999) Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13: 926-934.
30. Qin H, Wilson CA, Lee SJ, Benveniste EN, (2006) IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. Faseb J 20: 985-987.
31. Mantovani A, Garlanda C, Locati M, (2009) Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 29: 1419-1423.
32. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O, (2010) Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122: 1837-1845.